Durvalumab and Anlotinib Boost Small-Cell Lung Cancer Treatment
In a groundbreaking advancement poised to reshape the therapeutic landscape for extensive-stage small-cell lung cancer (ES-SCLC), a multicenter, randomized phase II clinical trial has unveiled compelling evidence favoring a combined maintenance regimen of …